News >

Cabozantinib Combinations Generate Excitement in RCC

Ellie Leick
Published: Wednesday, Apr 08, 2020

Rana R. McKay, MD

Rana R. McKay, MD

Since the FDA approval of cabozantinib (Cabometyx) for use patients with in renal cell carcinoma (RCC), research efforts have been examining the agent in combination with immunotherapy and dual immunotherapy to further improve patient outcomes, according to Rana R. McKay, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication